Nanobiotix SA announced April 4 that its Hensify NBTXR3nanoparticle radioenchancer for locally advanced soft-tissue sarcoma has received a CE Mark to allow commercialization in 27 European countries.
Hensify is the brand name for NBTXR3 as approved for treating locally advanced soft-tissue sarcoma. NBTXR3 is an aqueous suspension of crystalline hafnium oxide nanoparticles designed to be injected directly...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?